A Study of LY4175408 in Participants With Advanced Cancer

The purpose of this study is to measure the safety and efficacy of LY4175408 in participants with selected advanced cancer. In addition, this study will evaluate how much LY4175408 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. Participation could last up to 4 years.

Trial Details

NCT ID

NCT07046923

Phase

PHASE1

Sponsor

Eli Lilly and Company

Status

RECRUITING

Cancer Type

Triple Negative (TNBC) Breast Cancer

Interventions

LY4175408

Locations (sample)

Stanford, California, United States|37.42411,-122.16608
Orlando, Florida, United States|28.53834,-81.37924
Sarasota, Florida, United States|27.33643,-82.53065
Chicago, Illinois, United States|41.85003,-87.65005
Indianapolis, Indiana, United States|39.76838,-86.15804

Key Eligibility Criteria

Have one of the following advanced or metastatic solid tumor cancers:
Non-small cell lung cancer (NSCLC)
Small cell lung cancer (SCLC)
Endometrial cancer

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →